Target intelligence / Profile preview

Potassium voltage-gated channel subfamily Q (KCNQ) (KCNQ)

Target
KCNQ
Molecular classification
Ion channel, Voltage-gated ion channel, Potassium channel
01

Overview

KCNQ channels, specifically the Kv7.2 through Kv7.5 subtypes, are essential regulators of neuronal excitability within the peripheral nervous system, particularly in dorsal root ganglion (DRG) sensory neurons. These channels generate the M-current, a slow-activating and non-inactivating potassium current that serves as a physiological brake to prevent repetitive action potential firing and maintain the resting membrane potential. In peripheral sensory neurons, KCNQ channels play a pivotal role in nociception; their downregulation or inhibition leads to neuronal hyperexcitability, which is a hallmark of chronic and neuropathic pain. Pharmacological activation of these channels using positive allosteric modulators effectively hyperpolarizes the neuron, raising the threshold for firing and providing a potent mechanism for analgesia. Consequently, KCNQ channels are high-priority targets for developing non-opioid treatments for various pain syndromes and hyperexcitability disorders.

Other names
Kv7 channelM-channelVoltage-gated potassium channel subunit Kv7KQT-like subfamily
02

Mechanism of action

Positive allosteric modulation of KCNQ channels to stabilize the open state and shift the voltage-dependence of activation to more hyperpolarized potentials, thereby reducing neuronal firing.

03

Biological functions

Regulation of neuronal excitabilityMaintenance of resting membrane potentialM-current generationSignal transductionAction potential repolarization
04

Disease associations

Neuropathic painInflammatory painChronic painEpilepsyTinnitusTrigeminal neuralgia
05

Safety considerations

CNS side effects (dizziness, somnolence, fatigue)Urinary retention (due to KCNQ expression in bladder smooth muscle)Blue skin/retinal pigmentation (associated with long-term retigabine use)Potential for QT interval prolongation (if KCNQ1 is affected)
06

Interacting drugs

Retigabine

6 more in the full profile.

07

Biomarkers

Quantitative sensory testing (QST)Nerve conduction studiesSkin biopsy for intraepidermal nerve fiber density (IENFD)

Beyond the preview

Go deeper on Potassium voltage-gated channel subfamily Q (KCNQ) (KCNQ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium voltage-gated channel subfamily Q (KCNQ) (KCNQ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call